Stockscreener 앱 받기
4.26
0.95%
0.04
시간 외 거래:
4.28
0.02
+0.47%
Aquestive Therapeutics Inc 주식(AQST)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2026-06-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AQST | Press Release - Stockhouse
Aquestive (AQST) awards Abigail Jenkins 50,500 stock options at $3.99 - Stock Titan
Aquestive Therapeutics (AQST) director receives 50,500 stock options grant - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
AQST: FDA progress, global expansion, and all proposals passed with strong shareholder support - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gew - The National Law Review
AQUESTIVE THERAPEUTICS INC (AQST) Stock Chart - ChartMill
Aquestive Therapeutics: Rating Downgrade Despite Probability Of Anaphylm Approval - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect - ACCESS Newswire
2026-06-04 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect | NDAQ:AQST | Press Release - Stockhouse
Aquestive Therapeutics Q1 earnings call highlights - MSN
AQST: Aquestive TherapeuticsInteractive Chart - Zacks Investment Research
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review
2026-06-02 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aquestive Therapeutics Charts Cautious, Liquid Path Forward - TipRanks
Aquestive Therapeutics CEO sells $35,413 in company stock By Investing.com - Investing.com South Africa
Aquestive Therapeutics CEO sells $35,413 in company stock - Investing.com UK
PRN_FinancialWrapper - FinancialContent
Aquestive secures $150 million debt facility with Oaktree By Investing.com - Investing.com Nigeria
Aquestive targets Q3 FDA resubmission for Anaphylm and projects >$150M cash at launch - MSN
A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $6 to $9 - Moomoo
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Ardent Health Partners, Inc. (ARDT) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
All News about Aquestive Therapeutics, Inc.Common Stock - The Chronicle-Journal
Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Aquestive Says It’s on Track to Launch Anaphylm Studies for FDA - Allergic Living
Analysts Have Made A Financial Statement On Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) First-Quarter Report - Moomoo
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2026 Earnings Call Transcript - Insider Monkey
Citizens reiterates Aquestive stock rating on Anaphylm progress By Investing.com - Investing.com South Africa
Citizens reiterates Aquestive stock rating on Anaphylm progress - Investing.com
Aquestive Therapeutics Signals Momentum In Earnings Call - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript Summary - Moomoo
Aquestive Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AQST) 2026-05-14 - Seeking Alpha
Aquestive Therapeutics Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Aquestive’s Q1 2026 earnings beat forecasts, stock surges - Investing.com Nigeria
Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript - Benzinga
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Aquestive Therapeutics (AQST) reports Q1 loss, beats revenue estimates - MSN
Compared to estimates, Aquestive Therapeutics (AQST) Q1 earnings: A look at key metrics - MSN
2.11%
자본화:
|
볼륨(24시간):